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Background/aim: Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disease that requires lifelong colchicine
treatment. Colchicine is the mainstay of the treatment, which decreases the frequency and the severity of recurrent FMF attacks and
prevents the development of amyloidosis. This study aimed to investigate the rates of colchicine treatment adherence in patients with
FMF and the factors related to treatment non-adherence.
Materials and methods: This observational study was conducted with 179 patients with FMF between November 2018 and April
2019 in a tertiary rheumatology outpatient clinic. The sociodemographic and clinical data were recorded. Compliance Questionnaire
on Rheumatology (CQR) was used to assess the treatment adherence and the Beliefs About Medicines Questionnaire (BMQ-T) was
used to assess a patient’s beliefs about colchicine. The factors associated with adherence to the treatment were evaluated.
Results: The study included 113 male (63.1%) and 66 (36.9%) female patients with a mean age of 30 (25–44) years. The rate of the
patients who declared regular colchicine usage was 66.5%. The frequency of non-adherent patients was 83.8% according to CQR.
Treatment adherence was better in patients with comorbid diseases than those without (41.4% vs. 22%, respectively, p = 0.028). The
frequency of married patients in the adherent group (72.4%) was higher than the non-adherent group (47.3%) (p = 0.013). The
colchicine dose used in the adherent group was 1.5 (1.3–1.8) mg/day, whereas it was 1.5 (1.0–1.5) mg/day in the non-adherent group
(p = 0.033). The adherence rate was rising with increasing scores of BMQ-T Specific Necessity. As the scores of BMQ-T General Overuse
and General Harm increased, non-adherence to colchicine increased.
Conclusion: Evaluating adherence to colchicine treatment with objective methods is crucial to ensure sufficient treatment and prevent
amyloidosis. Determining beliefs about colchicine may increase patients’ adherence to treatment.
Key words: Adherence, familial Mediterranean fever, colchicine

1. Introduction
Familial Mediterranean fever (FMF) is a hereditary
autoinflammatory disease with recurrent febrile attacks
with peritonitis, pericarditis, pleuritis, arthritis, and
erysipelas-like erythema. The disease is frequent among
Turks, Armenians, Arabs, and Jaws, with a reported
prevalence of 0.093% in Turkey [1,2]. Colchicine is the
mainstay of FMF treatment due to being easy to use, safe
and cheap and plays a crucial role in both decreasing the
frequency and severity of febrile attacks also preventing
the development of amylodiosis [3]. The frequent attacks
and ongoing subclinical inflammation lead to the
development
of
amyloidosis,
most
significant
complication of FMF, may be responsible for chronic
kidney disease and increased rate of mortality among
patients. However, approximately 5% of FMF patients are
unresponsive to colchicine treatment, and they require
biological drugs [4]. It is important to determine the real
colchicine
resistance.
The
main
reason
for
unresponsiveness to colchicine treatment is using
colchicine non regularly [5]. Colchicine non-adherence

may cause unsatisfactory management and worsened
outcomes, such as the development of complications,
decreased quality of life, or increased costs for treatment
[3,6,7]. Since the biological agents are much more
expensive and have own risks, non-adherence to
colchicine is a non-negligible factor for classifying a
patient as unresponsive. Therefore, the factors related to
non-adherence to colchicine are problems that have to be
overcame primarily. Non-adherence to treatment may be
intentional due to the motivation, chocies, and beliefs of
the patient, or, may be unintentional due to the
insufficient knowledge, inability, and low capacity of the
patient. Beliefs About Medicines Questionnaire (BMQ)
was developed to determine the patients who were nonadherent to the treatment due to intentional factors [8]. In
this context, intentional non-adherence to colchicine is
associated with causes depending on patients’ beliefs
about medications and illness. So that, patients’ beliefs
about colchicine may be crucial in achieving treatment
adherence and treatment success. The current study
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aimed to determine the rates of colchicine treatment
adherence and related factors in patients with FMF.
2. Materials and methods
2.1. Design of the study, patient selection and data
collection
This cross-sectional observational study enrolled 179
patients with FMF who were following up at the
rheumatology outpatient clinic of Gülhane Training and
Research Hospital between November 2018 and April
2019. The patients who were diagnosed with FMF
according to Tel-Hashomer criteria [9], aged ≥ 18 years
old, who could speak, write in and read in Turkish were
included in the current study. Verbal consent and written
informed consent forms were obtained from each patient
before including the study in accordance with the
principles of the Helsinki Declaration. Exclusion criteria
were as follows: having a psychiatric disease, malignancy,
cognitive dysfunction, and being pregnant. The study was
approved by the Local Ethical Committee of Gülhane
Training and Research Hospital (approval number is
18/281). The sociodemographic and clinical data were
obtained from patients’ files and also through face-to-face
interviews. Compliance Questionnaire on Rheumatology
(CQR) and the Turkish version of Beliefs About Medicines
Questionnaire (BMQ-T) forms were applied to patients by
the same interviewer and took approximately 15–20 min.
The patients who had one and more FMF attacks each
month despite receiving colchicine in maximum tolerated
doses during six months are defined as colchicine
resistant [10].
2.2. Compliance Questionnaire on Rheumatology
CQR has developed by Klerk et al. to assess the treatment
adherence of patients with rheumatologic disease [11]. It
was translated to Turkish and validated by Cinar et al [12].
CQR consists of 19 items according to the treatment
adherence of the patients. The interviewer asks the
patient to state the degree of their agreement with each
statement on a 4-point Likert-type scale. Each statement
is pointed from 1–4 point, ranging from strongly disagree
[1] to strongly agree [4], but the items numbered 4, 8, 9,
11, 12, and 19 are negatively stated and should be recoded
reversely (4 = 1, 3 = 2, 2 = 3, 1 = 4) to provide a positive
score. A score ranging from 0 to 100 is calculated by
subtracting 19 from the sum of the items and dividing the
result by 0.57. Higher scores predict higher rates of
compliance with the treatment for patients with
rheumatologic diseases. A score of 0 indicates no
compliance, on the other hand, a score of 100 indicates
perfect compliance. Non-compliance is defined as a score
equal to or less than 80 [11].
2.3. Beliefs About Medicines Questionnaire
Beliefs About Medicines Questionnaire (BMQ) evaluates
the patients’ expectations and perceptions about
medications in two sections, BMQ Specific and BMQ
General. BMQ was validated by Cinar et al. for the Turkish
population (BMQ-T). The BMQ-T has a total of 18 items.
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BMQ-T Specific and BMQ-T General sections have two
subgroups for each. BMQ-T Specific consists of SpecificNecessity and Specific-Concern, which assess the beliefs
and concerns about a patient’s personal disease and
medications. BMQ-T General consists of General-Harm
and General-Overuse and assess the patient’s general
beliefs and perceptions about medications. A 5-point
Likert scale is used to assess the agreement for each
statement ranging from strongly disagree [1] to strongly
agree [5]. There were 5 statements for each in BMQ-T
Specisific-Necessity and Specific-Concern, and 4
statements for each in BMQ-T General-Harm and GeneralOveruse. For each subgroup, an average score is
calculated. Higher scores indicate stronger belief for the
calculated section [6,8].
2.4. Statistical analysis
IBM SPSS statistic 21 was used for statistical analysis (IBM
Corp., Armonk, NY, USA). The compatibility of the
continuous data with a normal distribution was examined
using the Kolmogorov–Smirnov test. Descriptive statistics
were presented as mean±standard deviation or median
(25th and 75th percentiles) values for measured variables
and frequency and percentage (%) for categorical data.
The Spearman correlation coefficient was used to evaluate
the association between variables. Mann–Whitney U test,
Pearson Chi-square test, and Fisher’s exact test were used
for analyzing the data. A p value <0.05 was accepted as
statistically significant.
3. Results
A total of 179 (113 Male/ 66 Female) patients were
included in the study. The median age was 30.0 (25.0–
44.0) years, and the median disease duration was 15.0
(9.0–22.0) years. The median time for diagnosis delay was
3.0 (1.0–9.0) years. Clinical manifestations were
peritonitis in 156 (87.2%) patients, fever in 154 (86%)
patients, and artralgia in 104 (58.1%) patients. Other
clinical manifestations were presented in Table 1. One
hundred fifty-five (91.7%) patients had a mutation in the
Mediterranean fever (MEFV) gene. The most common
mutation was M694V in 119 (66.5%) patients. Proteinuria
was detected in 25 (14%) patients. Eight (4.5%) patients
had amyloidosis (Table 1).
The median dose of colchicine was 1.5 (1.0–1.5)
mg/day. The percentage of the patients who declared that
they have been using colchicine regularly was 66.5%.
Colchicine resistance was present in 21 (11.7%) patients.
Forty (22.3%) patients reported an adverse event due to
colchicine. The most frequent adverse event was diarrhea
in 23 (12.8%) patients. The other adverse events were
abdominal pain (2.8%), vomiting (1.1%), hair loss (1.1%),
vitamin B12 deficiency (1.1%), myopathy (1.1%),
elevation of liver transaminases (0.6%), constipation
(0.6%), arthralgia (0.6%) and urticaria (0.6%) (Table 1).
The mean score of CQR was 67.4 ± 11.7 in the study
group. According to CQR, the number of non-adherent
patients to colchicine was 150 (83.8%). The frequency of
married patients was higher in the adherent group than
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Table 1. Sociodemographic and clinical characteristics of patients.
Patients
(n = 179)
30.0 (25.0–44.0)

Age (years) *
Sex, n (%)

Male

113 (63.1)

Female

66 (36.9)

Disease duration (years) *
Educational Status, n (%)

Marital status, n (%)
Access to the treatment center, n (%)
Living place, n (%)

Socioeconomic status, n (%)

Employement status, n (%)
Clinical manifestation, n (%)
Peritonitis
Fever
Arthralgia
Febrile myalgia
Arthritis
Pleuritis
Diarrhea
Erysipelas like erythema
Pericarditis
Orchitis
Presence of proteinuria, n (%)

15.0 (9.0–22.0)
≤8 years

39 (21.8)

9–11 years

29 (16.2)

>11 years

111 (62.0)

Married

92 (51.4)

Unmarried

87 (48.6)

Easy

147 (82.1)

Difficult

32 (17.9)

Rural

24 (13.4)

Urban

155 (86.6)

Less than income

36 (20.1)

Equal to income

124 (69.3)

More than income

16 (10.6)

Employed

113 (63.1)

Unemployed

66 (36.9)
156 (87.2)
154 (86.0)
104 (58.1)
73 (40.8)
68 (38.0)
63 (35.2)
51 (28.5)
42 (23.5)
3 (1.7)
2 (1.8)
25 (14.0)

Presence of amyloidosis, n (%)

8 (4.5)

Patients resistant to colchicine, n (%)

21(11.7)

Presence of MEFV gene mutations, n (%)

155 (91.7)

Patients with comorbidities, n (%)

45 (25.1)

Colchicine dose, (mg/day)*

1.5 (1.0–1.5)

*median (25th–75th percentile), MEFV: Mediterranean Fever

the non-adherent group (72.4% vs. 47.3%, p = 0.013). The
rate of the patients with comorbidities were 41.4% in the
adherent group, whereas 22.0% in the non-adherent
group (p = 0.028). However, in terms of the type of
comorbid disease, there was no statistically significant
difference between groups. The median dose of colchicine
was 1.5 (1.3–1.8) mg/day in the adherent group and 1.5
(1.0–1.5) mg/day in the non-adherent group (p = 0.033).
Considering age, sex, clinical manifestations, disease
duration, socioeconomic or employment status, the place
patient lived in, presence of proteinuria, chronic renal
failure, and amyloidosis, resistance to colchicine, having a
mutation on MEFV gene, a positive family history for FMF,
there were no statistically significant differences between

the adherent and non-adherent groups (p > 0.05) (Table
2).
BMQ-T Specific Necessity scores were statistically
significantly higher in the adherent group than the nonadherent group (p < 0.001) (Table 3). Adherence with
colchicine treatment has a positive correlation with the
scores of BMQ-T Specific Necessity (r = 0.495, p < 0.001)
(Table 4). BMQ-T General Overuse and General Harm
scores were statistically significantly higher in the nonadherent group compared with the adherent group (p =
0.003 and p = 0.001, respectively) (Table 3). The
correlations were negative between adherence to
colchicine and the scores of BMQ-T General Overuse (r = –
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Table 2. Relationships between sociodemographic and clinical characteristics of patients and CQR score.

Patients, n (%)

CQR score
Adherence
(≥80 %)
29 (16.2)

Non-adherence
(< 80 %)
150 (83.8)

Age (years)*

37.0 (28.5–44.5)

29.0 (24.0–44.0)

Male

15 (51.7)

98 (65.3)

Female

14 (48.3)

52 (34.7)

≤8 years

7 (17.9)

32 (82.1)

9-11 years

3 (10.3)

26 (89.7)

>11 years

19 (17.1)

92 (82.9)

Married

21 (72.4)

71 (47.3)

Unmarried

8 (27.6)
25
(86.2)
4 (13.8)

79 (52.7)

23 (15.3)

More than income

1 (3.4)
28
(96.6)
8 (22.2)
17
(13.7)
4 (21.1)

Employed

15 (51.7)

98 (65.3)

Unemployed

14 (48.3)

52 (34.7)

Presence of MEFV mutation, n (%)

22 (75.9)

133 (88.7)

0.992b

Presence of comorbidity, n (%)

12 (41.4)

33 (22.0)

0.028b

1.5 (1.0–1.5)

0.033a

Sex, n (%)

Educational Status, n (%)

Marital status, n (%)

Easy

Access to the treatment center, n (%)

Difficult
Rural
Living place, n (%)

Urban
Less than income

Socioeconomic status, n (%)

Equal to income

Employement status, n (%)

p-value
0.099a
0.164b

0.641b

0.013b

122 (81.3)

0.372b

28 (18.7)
0.133c

127 (84.7)
28 (77.8)
107 (86.3)

0.395b

15 (78.9)

Colchicine dose (mg/day)*
1.5 (1.3–1.8)
aMann–Whitney U test, bPearson Chi-Square test, cFisher’s Exact test.
* median (25th–75th percentile),
CQR: Compliance Questionnaire on Rheumatology, MEFV: Mediterranean Fever.

0.164b

Table 3. Beliefs About Medicines Questionnaire scores in adherent and non-adherent patients.

BMQ-T Specific Necessity*

4.0 (3.4–4.6)

CQR score
Adherence
≥80 %
(n = 29)
4.8 (4.1–5.0)

BMQ-T Specific Concerns*

2.8 (2.4–3.6)

2.8 (2.2–3.8)

2.8 (2.4–3.6)

–0.100

0.920

BMQ-T General Overuse*

2.5 (2.25–3.25)

2.25 (1.75–2.63)

2.75 (2.25–3.25)

<2.936

0.003

Overall
(n = 179)

Non-adherence
< 80 %
(n = 150)
3.8 (3.35–4.25)

Z

p

–5.260

<0.001

BMQ-T General Harm*
2.25 (2.0–3.0)
1.75 (1.38–2.63)
2.38 (2.0–3.0)
–3.212
0.001
Z = Mann–Whitney U test
* median (25th–75th percentile)
CQR: Compliance Questionnaire on Rheumatology, BMQ-T: Turkish translation of Beliefs About Medicines Questionnaire.

0.273, p  0.001) and General Harm (r = –0.291, p < 0.001)
(Table 4).
4. Discussion
The mainstay of FMF treatment is colchicine, which
increases the quality of life of the patients and prevents
amyloidosis via decreasing the frequency and severity of
febrile attacks. Disrupting colchicine use regarding
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various causes is an important issue due to the role of
colchicine in preventing morbidity and mortality
associated with FMF. Therefore, determining whether the
patient is using colchicine in appropriate dose, the factors
related to non-adherence to colchicine treatment and
recommendations for solving the problems related to
non-adherence come into prominence. The current study
found out that most of the patients were non-adherent to
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Table 4. Correlation analysis between Beliefs About Medicines
Questionnaire scores and Compliance Questionnaire on
Rheumatology Scores.
CQR score
r

p

BMQ-T Specific Necessity*

0.495

0.001

BMQ-T Specific Concerns*

–0.007

0.923

BMQ-T General Overuse*

–0.273

0.001

BMQ-T General Harm*
–0.291
0.001
r = Spearman correlation test
* median (25th–75th percentile)
CQR: Compliance Questionnaire on Rheumatology, BMQ-T:
Turkish Beliefs About Medicines Questionnaire.

colchicine, patients’ thoughts about overusing colchicine
and potential harm of colchicine. Having comorbidities
and being married are factors increasing the adherence
with colchicine. Ensuring the treatment adherence will
accomplish treatment success and avoid misevaluation of
colchicine resistance, decrease morbidity and mortality,
which may occur due to not using colchicine, and prevent
unnecessary health care costs. To the best of our
knowledge, this is the first study to investigate adherence
to colchicine treatment by using CQR and related factors
in adult patients with FMF.
Previously, 5%–15% of FMF patients revealed as nonresponders to colchicine [5,13]. However, after excluding
the patients who were non-adherent to colchicine, the
prevalence of resistance was determined as
approximately 5% [14]. In the current study, 11.7% of the
patients were accepted as colchicine resistant, which is
higher than the reported rates in the literature.
Considering the low ratio of colchicine adherence in our
study group, it may be speculated that some colchicine
resistant patients are actually non-adherent patients.
Evaluating patients’ adherence to the treatment is crucial
for determining treatment response and planning future
treatment options. Before the commencement of
biological drugs, treatment adherence should be
evaluated cautiously [10]. Adherence with a drug that has
measurable blood levels (digoxin, valproic acid, etc.) or
targets (hypouricemic agents, anti-diabetic agents, etc.)
can be determined more objectively. However, there is no
laboratory assessment to measure the serum levels of
colchicine. Therefore, colchicine adherence can only be
assessed by patient-reported questionnaires. Morisky
Green Levine Medication Adherence Scale is an option for
the assessment of treatment adherence, but it does not
give detailed information about the factors related to nonadherence of the treatment [15]. CQR is a questionnaire
that is developed specifically for assessing compliance in
rheumatologic diseases [11].
In the current study, the rate of the patients who were
adherent to colchicine treatment was only 16.2%. In the
literature, there was limited data regarding treatment
adherence in patients with FMF and in general, these
studies used subjective reports of the patients, instead of
relatively an objective scale or questionnaire. Ben-Chetrit

reported fully adherence ratio of 13% in FMF patients [5].
A study performed among 96 FMF patients were found an
adherence rate of 64.5% by asking the patients if they
were using or not using the colchicine treatment [16].
Similar to this finding, in our study, when the patients
were asked if they use colchicine regularly or not, 66.5%
of the patients declared that they were using colchicine
regularly, which is a quite higher rate than detected with
CQR. A feeling of guilt regarding being non-adherent may
impel patients to hide the truth from the physicians.
Additionally, CQR is a detailed questionnaire beyond
evaluating taking the pills or not, but also, evaluates the
factors related to non-adherence to the treatment,
presence of a treatmet interruption, patient’s belief about
the benefit of the treatment and expectations from the
treatment, and presence of the obstacles in receiving the
treatment. Therefore, evaluating treatment adherence by
using CQR may be more accurate both for the physician
and the patient.
Recently, among children with FMF, an adherence rate
of 30% was reported [17]. The higher rates among
pediatric patients may be related to administering the
drugs by their parents. In another study evaluating the
adherence rate among pediatric patients with FMF, the
adherence rate was higher in younger patients [18].
Corsia et al. reported the adherence rate for colchicine
treatment as 40% in the study group, whereas, in terms of
adult and childhood patients, the adherence rates were
22% and 48%, respectively. On the other hand, Corsia et
al. did not use any specific scale or questionnaire for
evaluating the adherence rates [19].
In the current study, treatment adherence was better
among patients with concomitant diseases than without
concomitant diseases. Patients with concomitant diseases
may have more concerns about the worsened outcomes of
FMF. On the other hand, the type of concomitant disease
did not differ between the groups. Patients with
concomitant diseases may be more cautious about taking
their treatment regularly. Also, adherent patients had
higher doses of colchicine than non-adherent patients,
according to the current study. The patients using higher
doses of colchicine may have more severe disease, more
frequent attacks, and also, these patients may have more
concerns about the worsened outcomes of FMF. Also, they
may have a low quality of life. The current study indicated
that married patients were more adherent to treatment
than unmarried patients. This situation may be associated
with the assistance of the partner to take the pills
regularly or due to increased sense of responsibility in
married patients. Similarly, due to the administration of
the drug by parents, the adherence rate was reported as
90.5% among patients under five years old [18].
Reminding (a partner, a parent, a phone alarm, or an
application, vs.) may increase the adherence.
In patients who had developed amyloidosis due to
FMF, colchicine still may effectively improve proteinuria
and prevent progression to chronic renal failure [20].
Therefore, patients who had amyloidosis should continue
2361
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using an appropriate dose of colchicine regularly. Ugurlu
et al. reported an adherence rate of 33.3% in patients with
FMF and secondary amyloidosis [21]. A study that
investigated the colchicine treatment adherence rate of
FMF patients with amyloidosis showed that the patients
had an adherence rate of 44%. Whereas, patients who had
a diagnosis with amyloidosis simultaneously with FMF
had an adherence rate of 93% [22]. In the current study,
there was no relationship between the presence of
amyloidosis and treatment adherence. Furthermore, the
adherence rate is lower than the studies that assessed
adherence in other rheumatologic diseases [12,23]. The
rate of the patients, who were adherent to biological
drugs, was 59.3% in rheumatoid arthritis, 62.5% in
psoriatic arthritis, and 76.2% in ankylosing spondylitis
[24]. Xian et al. reported an adherence rate of 43.1%
among systemic lupus erythematosus patients [25]. On
the other hand, Yin et al. reported a rate of 9.6%
adherence to urate-lowering therapy among patients with
gout [26].
Early-onset of the disease and having a chronic course
may lead to a decrease in treatment adherence in chronic
diseases. Colchicine treatment should be life-length, and
patients need to use pills two or three times a day. These
may decrease the compatibility with colchicine treatment.
Also, drug-related adverse events may be reasons for
decreasing compatibility. In the current study, there was
no association between adverse events related to
colchicine and treatment adherence. Whereas, Sonmez et
al. reported that pediatric patients with FMF who had
more adverse events had lower rates of treatment
adherence [18].
The treatment adherence of the patients with chronic
diseases may be influenced by psychosocial factors,
concerns about side effects, unawareness of treatment
requirement, patients’ attitudes regarding their illness
and beliefs about medicine. Approximately 40% of the
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